

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
BORTEZOMIB FOR INJECTION OBTAINS APPROVAL
FOR DRUG REGISTRATION**

This announcement is made by the board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that Bortezomib for Injection (the “**Product**”), an anticancer drug developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., a subsidiary of the Company, has obtained approval for drug registration by the National Medical Products Administration of the People’s Republic of China. It is the second time that subsidiaries of the Group obtain such approval for drug registration regarding the development of the Product.

Bortezomib is a new anticancer drug in targeted therapy, being mainly used for treating multiple myeloma and mantle cell lymphoma. The approval obtained for the Product reflects that the Group has further made solid progress in the field of blood cancer treatment. It is expected that the Product will be launched in the near future and more patients in China will benefit from it.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairlady

Hong Kong, 12 October 2018

As at the date of this announcement, the Board of the Company comprises seven Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.